17:37 , Sep 21, 2018 |  BC Week In Review  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator...
13:46 , Sep 20, 2018 |  BC Extra  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription 3...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
19:45 , Sep 10, 2018 |  BC Extra  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
22:56 , Sep 5, 2018 |  BC Extra  |  Preclinical News

Two papers open door to T cell brain entry for glioblastoma therapy

Two new studies have proposed solutions to different barriers that prevent T cells from entering the brain to attack glioblastoma. Glioblastoma patients often have low T cell counts, and their tumors’ ability to evade immune system...
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; acute lymphoblastic leukemia (ALL); ovarian cancer; solid tumors Cell culture and mouse studies suggest anti-PD-1 single-chain variable fragment (scFv)-secreting CAR T cells could help treat Burkitt lymphoma, ALL and solid tumors. In co-culture with...
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
18:35 , Aug 10, 2018 |  BC Week In Review  |  Financial News

China's CureGenetics raises $17M for CRISPR

CureGenetics Co. Ltd. (Suzhou, China) raised $17 million in a series A round led by new investor Qiming Venture Partners. CTS Capital and Ascendin Investment also participated. CureGenetics uses its CRISPR-based gene editing technology to knock...
15:09 , Aug 6, 2018 |  BC Extra  |  Financial News

Chinese CRISPR play CureGenetics raises $17M series A

CureGenetics Co. Ltd. (Suzhou, China) raised $17 million in a series A round led by new investor Qiming Venture Partners. CTS Capital and Ascendin Investment also participated. CureGenetics uses its CRISPR-based gene editing technology to knock...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest T cells engineered to express an anti-PSCA chimeric antigen receptor (CAR) and TGFβ-RII- and CD124-based fusion proteins could help treat pancreatic cancer. The CAR T cells...